Our Company

Mr. Fellows has more than 25 years of industry experience and currently serves on the board of Jaguar Gene Therapy, Axovia Therapeutics and the Glaucoma Foundation, and as the chairman of the board for Oxular Limited. He was previously on the board of Gyroscope Therapeutics and Arctos Medical. Mr. Fellows was most recently the Chief Executive Officer of Nightstar Therapeutics, a retinal gene therapy company acquired by Biogen in 2019. Prior to joining Nightstar Therapeutics, he was the Vice President of Johnson & Johnson’s Vision Care Franchise where he led global marketing, new product and licensing activities. Before joining Johnson & Johnson, he held leadership positions at Allergan, Inc. for 25 years where he served primarily in the sales and marketing areas in a number of capacities, including Regional President, Corporate Vice President, and Senior Vice President across North America, Europe and Asia. David holds a B.A. in Psychology from Butler University.

Eduardo has more than 30 years of operations experience in GMP regulated industries. Prior to joining AGTC, he was most recently employed by Sangamo Therapeutics, a genomic medicine company with viral vector and cell therapy programs, serving as Vice President, Global Manufacturing and was a member of the Technical Operations Executive Leadership team.   Eduardo was responsible for the company product supply and had direct responsibilities over USA and EU internal manufacturing sites and external manufacturing operations.  Mr. Jacobo has experience in cGMP regulations, with expertise in tech transfer, process development, designing and building manufacturing facilities, planning, supply chain, and operations of clinical and commercial sites.  Eduardo brings extensive progressive leadership experience within pharmaceutical, biotechnology, and medical device operations from Eli Lilly, Amgen, Zimmer, Ametek and Sangamo.  Mr. Jacobo received his B.S. in Mechanical Engineering from the Georgia Institute of Technology and obtained his MBA from the Inter American University.

Mr. Reynolds has served as the Company’s Vice President, Accounting since March 2020. Prior to joining the Company, Mr. Reynolds was Director of External Financial Reporting at Gartner, Inc., a global research and advisory firm, from March 2017 to March 2020. From January 2016 to February 2017, Mr. Reynolds was Vice President of Financial Reporting at WCI Communities, Inc., a lifestyle community developer and luxury homebuilder, and from October 2013 to December 2015 he was Director of Financial Reporting at WCI Communities, Inc. Prior to that, Mr. Reynolds was Director of Financial Reporting at Health Management Associates, Inc., a hospital owner and healthcare services provider to patients in hospitals and other health care facilities in non-urban communities located primarily in the southeastern United States, from May 2005 to April 2013. Mr. Reynolds received a B.B.A. in accounting from Adelphi University and an M.S. in taxation from Long Island University, C.W. Post Campus.

Dr. Scaria has more than 25 years of experience in gene therapy, ranging from discovery research to early-stage clinical trials. For much of his career, Dr. Scaria has specialized in viral gene delivery vectors and ocular gene therapy, having served as Senior Scientific Director of Gene Therapy at Genzyme, Head of Gene Therapy Research at Sanofi-Genzyme and VP of Ophthalmology/Gene Editing at Casebia Therapeutics. Most recently, Dr. Scaria was SVP and Chief Scientific Officer at IVERIC bio. He earned his doctorate in biochemistry and molecular biology from Indiana University School of Medicine and conducted postdoctoral research at St. Louis University School of Medicine and at the University of Washington School of Medicine in Seattle. Dr. Scaria has more than 50 publications and 20 patents and currently serves on several committees for the American Society for Gene and Cell Therapy.

Nadia Waheed, MD, MPH has extensive experience as a retina specialist and in ocular imaging and clinical research. Most recently, she was Chief Medical Officer at Gyroscope Therapeutics, a retinal gene therapy company acquired by Novartis in 2022. She also has experience as Director of the Boston Image Reading Center and Professor in Ophthalmology and Consultant at the New England Eye Center, Tufts University School of Medicine.

Dr. Waheed received her medical degree from the Aga Khan University Medical School, Pakistan, and a Master in Public Health from the Harvard School of Public Health. She trained in Ophthalmology at the Harvard Medical School/Mass Eye and Ear Infirmary Program in Ophthalmology and completed a fellowship in retina at the Harvard Medical School/Mass Eye and Ear Infirmary. She then joined the Cleveland Clinic Cole Eye Institute as faculty and later established the Retina Unit at the Shifa Hospital, following which she joined the New England Eye Center.

Dr. Waheed has authored over 100 papers in peer-reviewed publications, has co-authored and edited three books in Ophthalmology, and has participated as a principal investigator or co-investigator in multiple clinical trials. She has been recognized by both the American Academy of Ophthalmology and the Macula Society with an Achievement Award.